Ukwelashwa Kwezidakamizwa Okusha Kwezimila Eziqinile Ezithuthukile

January 21, 2022
by umhleli
Engeza amazwana
I-3 min ifunde
en English
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
Ibhalwe ngu umhleli

I-Nuvation Bio Inc. namuhla imemezele ukuthi i-US Food and Drug Administration (FDA) isisusile isicelo sayo esisha somuthi (IND) sokuhlola i-NUV-868, i-BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor, for ukwelashwa kwezimila eziqinile ezithuthukisiwe, okuhlanganisa umdlavuza we-ovarian, umdlavuza we-pancreatic, umdlavuza we-prostate resistant metastatic castration (mCRPC), kanye nomdlavuza webele ongemuhle kathathu (TNBC).

Phrinta Friendly, PDF & Imeyili

"Ukugunyazwa kwesicelo sethu se-IND se-NUV-868 kuyingqopha-mlando ebalulekile ku-Nuvation Bio njengoba kuphawula i-IND yesine ezinyangeni eziyi-14 ezedlule epayipini lethu elijulile lokwelapha umdlavuza okuhloswe ngazo izinhlobo eziningi zesimila," kusho uDavid Hung, MD, umsunguli. , umongameli, kanye nesikhulu esiphezulu se-Nuvation Bio. "Sikhuthazwa ukukhetha kanye nokubekezelelana okuthuthukisiwe okukhonjiswe yi-NUV-868 ezifundweni zangaphambi komtholampilo, futhi sibheke ngabomvu ukuqhubekisela phambili lolu hlelo ekuthuthukisweni kweSigaba 1 maphakathi no-2022."

I-NUV-868 ivimbela i-BRD4, eyilungu eliyinhloko lomndeni we-BET olawula i-epigenetically amaprotheni alawula ukukhula nokuhlukaniswa kwesimila. I-NUV-868 yakhelwe ukuthi ikhethe kakhulu i-BD2 kune-BD1 emzamweni wokugwema ubuthi obukhawula bokwelapha bamanye ama-BRD4 inhibitor afana nobuthi besisu (GI) nomnkantsha. Ucwaningo lwangaphambi komtholampilo lubonise ukuthi i-NUV-868 ikhetha cishe izikhathi ezingu-1,500 ku-BD2 kune-BD1. Ama-BD1/2 inhibitors angakhethi ekuthuthukisweni ahlotshaniswe nezinkinga zokubekezelelana, okungenzeka ngenxa yokuvinjelwa kwe-BD1 kakhulu.

Ngokusulwa kwale IND ye-NUV-868 kumathumba aqinile athuthukile, i-Nuvation Bio izobe iqala ucwaningo lweSigaba 1/2 se-NUV-868 njenge-monotherapy futhi ihlanganiswe ne-olaparib noma i- enzalutamide ezinhlotsheni eziningi zesimila. Le phrothokholi (NUV-868-01) izoqala ngocwaningo lokwenyuka komthamo we-monotherapy weSigaba 1 ezigulini ezithuthukisiwe zesimila esiqinile. Kuzobe sekuqalwa ucwaningo lweSigaba 1b oluhlola i-NUV-868 ngokuhlangana ne-olaparib ekulapheni umdlavuza wesibeletho, umdlavuza we-pancreatic, i-mCRPC, neziguli ze-TNBC futhi kuhlanganiswe ne- enzalutamide yeziguli ze-mCRPC okulandelwa ucwaningo lweSigaba 2b ukuze kuqhutshekwe nokuhlola ukuphepha nokusebenza ngempumelelo. uma umthamo wenhlanganisela weSigaba 2 onconywayo usunqunyiwe. Ucwaningo lweSigaba 2 lwe-monotherapy luzophinda luqalwe ezigulini ze-mCRPC ukuze kuqhutshekwe nokuhlola ukuphepha nokusebenza ngempumelelo.

Phrinta Friendly, PDF & Imeyili

Kukhona Ongakuthanda

Mayelana umbhali

umhleli

Umhleli omkhulu we-eTurboNew nguLinda Hohnholz. Uzinze e-eTN HQ e-Honolulu, e-Hawaii.

Buka konke okuthunyelwe

Shiya amazwana

eTurboNews | eTN